AI assistant
Sending…
LISATA THERAPEUTICS, INC. — Director's Dealing 2017
Jan 27, 2017
34931_dirs_2017-01-27_eaad6029-7b42-47b2-af11-4a0f4f34ed08.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-01-25
Reporting Person: Mazzo David J (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-01-25 | Common Stock | F | 761 | $3.87 | Disposed | 75019 | Direct |
Footnotes
F1: Includes 38,613 shares of unvested restricted stock.